Endocrine/metabolic Scientists at Jiangsu Hengrui Pharmaceuticals Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. have divulged glucagon-like peptide 1 receptor (GLP-1R) agonists reported to be useful for the treatment of type 1 diabetes, …

Cancer Shanghai Fosun Pharmaceutical (Group) Co. Ltd. has synthesized poly(ADP-ribose) glycohydrolase (PARG) inhibitors reported to be useful for the treatment of cancer. BioWorld Science Cancer Patents

Breakthrough Innovation Aims to Enable the Earliest Possible Detection of Breast Cancer CYduct Diagnostics (OTCMKTS:CYDX) WESTPORT, CT, UNITED STATES, June 18, 2025 /⁨EINPresswire.com⁩/ -- CYduct Diagnostics, Inc. (OTCPK: CYDX), a leader in …

Artificial intelligence and robotics are changing how pharmaceutical companies conduct research and development. While public attention often centers on faster drug discovery and personalized treatments, some of the most consequential shifts are happening …

Advertisement U.S. pharmaceutical companies are increasingly turning to China to source next-generation medicines. In the first half of 2025 alone, they signed 14 licensing agreements with Chinese drugmakers—deals potentially worth $18.3 billion—compared …

India and the US are on the verge of a trade agreement that will transform commerce between the two largest democracies in the world. The next few weeks of June and July 2025 will be pivotal for their trade relationship as negotiations enter advanced …

New intellectual property builds on Palvella’s multi-layered exclusivity strategy Patent term expected through at least 2038 WAYNE, Pa., June 18, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: PVLA) Palvella Therapeutics, Inc. (Palvella), a clinical-stage …

Robust intellectual property portfolio, built over more than a decade, designed to protect core innovations for treating metabolic diseases New U.S. patents strengthen Fractyl’s leadership in metabolic innovation by expanding its patent coverage of …

In case MSN launches the generic version of the drug in July 2025, Divi's Laboratories' estimated earnings from Entresto API could be ₹700 crore in FY26. If the MSN launch is delayed, Divi's can make around ₹1,000 crore to ₹1,200 crore in FY26. …

Shinpoong Pharmaceutical said Tuesday that it received a decision from the European Patent Office (EPO) to grant a patent for Pyramax (pyronaridine phosphate-artesunate), which was approved for treating malaria last Friday. The patent is titled “ …